COSMO Pharmaceuticals SA

Cosmo N.V. is a life sciences company that develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. Its products include GI Genius, an AI-based system for real-time detection of colorectal lesions; Winlevi for acne vulgaris; Lialda/Mezavant/Mesavancol for ulcerative colitis; Uceris/Cortiment for colonic delivery of budesonide; Eleview for gastrointestinal lesion excision; Lumeblue for colorectal lesion visualization; Aemcolo/Rifamycin for travelers' diarrhea; and Clascoterone, in phase-3 trials for male pattern hair loss. It is also developing treatments in phase-2 and phase-1 trials for inflammatory bowel disease, bile acid diarrhea, and solid tumors. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. Founded in 1997, it is headquartered in Dublin, Ireland.